Ostatní
Návod 
Organogenesis Holdings Inc.
ORGO
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.8B
Obrat
1B
Zisk
0B
Aktiva
1B
Dluh
0B
ROE
0%
ROA
0%
PE
487
PS
1
Cena 1R
3-7
⌀ Cena
4.40
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
26-02-2026
Poslední dividenda
Profil
Organogenesis Holdings Inc., společnost zabývající se regenerativní medicínou, vyvíjí, vyrábí a komercializuje řešení pro pokročilou péči o rány a trhy chirurgické a sportovní medicíny ve Spojených státech. Mezi produkty společnosti pro pokročilou péči o rány patří Affinity, amniotická membránová rána, v níž se uchovávají životaschopné růstové faktory/cytokiny buněk a ECM proteiny v nativní tkáni; Apligraf, bioinženýrská terapie živých buněk, která produkuje spektrum cytokinů a růstových faktorů; Dermagraft, bioinženýrský produkt, který produkuje lidský kolagen, ECM, proteiny a cytokiny; NuShield, tkáň pokrývající ránu zahrnuje jak aminionové, tak chorionové membrány pro houbovitou/mezivrstvu neporušenou; PuraPly , antimikrobiální bariéra umožňuje konformovatelnost a odvod tekutin; a Novachor, což je plodová membránová poranění, v nichž se uchovávají životaschopné buňky, růstové faktory/cytokiny a ECM proteiny. Mezi jeho přípravky pro chirurgickou a sportovní medicínu patří NuCel, dehydrovaná placentární tkáň chirurgicky aplikovaná na cílovou tkáň, aby podpořila přirozené hojení; ReNu, kryoparevná suspenze používaná pro podporu hojení měkkých tkání; a FiberOS a OCMP používané jako výplň kostních prázdnin především v ortopedických a neurochirurgických aplikacích. Mezi produkty společnosti patří PuraPly XT a PuraPly MZ pro léčbu chronických, akutních a otevřených ran; PuraForce, bioinženýrská vakuová chirurgická matrice z prasečího kolagenu pro použití v aplikacích posilování měkkých tkání; a TransCyte, bioinženýrská tkáň pro léčbu popálenin částečné tloušťky. Slouží nemocnicím, centrům péče o rány, vládním zařízením, ambulantním servisním střediskům a ordinacím lékařů prostřednictvím přímých prodejních sil a nezávislých agentur. Společnost byla založena v roce 1985 a sídlí v Kantonu v Massachusetts.
Sektor
Healthcare
Odvětví
Drug Manufacturers - Specialty & Generic
Počet zaměstnanců
869
Založení
2017-01-05
Podobné společnosti
$ 1.85
+ $ 0.07
$ 10.64
+ $ 0.48
$ 2.79
+ $ 0.13
$ 7.04
+ $ 0.48
$ 6.46
- $ 0.08
$ 12.35
+ $ 0.33
$ 6.48
+ $ 0.04
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 563.9 | 564.2 | 482.0 | 433.1 | 450.9 | 468.1 | 338.3 | 261.0 | 193.4 | 0.0 | 0.0 | |
| Cost of Revenues | 144.5 | 149.1 | 115.7 | 106.5 | 105.0 | 114.2 | 87.3 | 75.9 | 68.8 | 4.6 | 0.2 | |
| Gross Profit | 419.4 | 415.1 | 366.3 | 326.7 | 345.9 | 353.9 | 251.0 | 185.0 | 124.6 | -4.6 | -0.2 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 225.6 | 150.9 | 100.8 | 86.7 | 126.7 | 115.2 | 130.2 | 110.0 | 99.7 | 108.5 | |
| Cost of Revenues | 56.9 | 36.3 | 27.6 | 23.7 | 31.1 | 26.8 | 29.2 | 28.7 | 31.9 | 25.8 | |
| Gross Profit | 168.7 | 114.6 | 73.1 | 63.0 | 95.6 | 88.4 | 101.0 | 81.3 | 67.8 | 82.7 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 44.4 | 39.8 | 30.7 | 20.1 | 14.8 | 10.7 | 0.0 | 0.0 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 269.8 | 283.8 | 250.2 | 203.5 | 199.7 | 162.0 | 0.0 | 0.0 | |
| Depreciation & Amortization | 20.7 | 26.9 | 17.0 | 23.4 | 18.0 | 16.7 | 7.6 | 9.4 | 7.0 | 0.0 | -0.4 | |
| Total Operating Expenses | 372.8 | 358.7 | 367.6 | 314.1 | 323.6 | 280.9 | 223.6 | 214.5 | 172.7 | 0.0 | 0.2 | |
| Operating Income | 46.6 | 56.4 | -1.3 | 12.5 | 22.3 | 72.9 | 27.4 | -29.5 | -51.6 | -4.6 | 0.2 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11.8 | 10.5 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 53.1 | 64.2 | ||
| Depreciation & Amortization | 7.0 | 4.9 | 4.6 | 4.3 | 4.4 | 4.4 | 4.2 | 4.0 | 6.3 | 5.8 | ||
| Total Operating Expenses | 103.4 | 93.9 | 85.7 | 89.7 | 85.4 | 82.1 | 114.9 | 85.1 | 67.1 | 74.7 | ||
| Operating Income | 65.2 | 20.7 | -12.6 | -26.7 | 10.2 | 6.2 | -13.9 | -3.9 | 0.6 | 8.1 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 2.5 | 0.0 | |
| Interest Expense | 0.7 | 2.3 | 1.5 | 2.2 | 2.0 | 7.2 | 11.3 | 9.0 | 10.9 | 0.0 | 0.0 | |
| Other Expense | 1.1 | -9.4 | -1.5 | -2.1 | -2.0 | -9.1 | -8.9 | -10.8 | -5.9 | 2.5 | -0.4 | |
| IBT | 47.8 | 47.0 | -2.8 | 10.4 | 20.3 | 63.8 | 18.5 | -40.3 | -64.7 | -2.1 | -0.2 | |
| Income Tax Expense | 10.8 | 9.9 | -3.7 | 5.4 | 4.8 | -31.1 | 0.5 | 0.2 | 0.1 | 0.0 | 0.0 | |
| Net Income | 37.0 | 37.0 | 0.9 | 4.9 | 15.5 | 94.9 | 17.9 | -40.5 | -64.8 | -2.1 | -0.2 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 0.7 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Interest Expense | 0.2 | 0.4 | 0.0 | 0.0 | -0.1 | 0.5 | 0.6 | 0.5 | 0.5 | 0.4 | ||
| Other Expense | -1.8 | 1.2 | 0.7 | 1.0 | 0.0 | -0.4 | -0.6 | -0.5 | -0.5 | -0.4 | ||
| IBT | 63.4 | 22.0 | -11.8 | -25.8 | 10.3 | 5.8 | -14.5 | -4.3 | -1.8 | 7.6 | ||
| Income Tax Expense | 19.7 | 0.4 | -2.4 | -6.9 | 2.6 | -6.5 | 2.5 | -2.2 | -1.2 | -4.5 | ||
| Net Income | 43.7 | 21.6 | -9.4 | -18.8 | 7.7 | 12.3 | -17.0 | -2.1 | -0.6 | 12.1 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.04 | $0.12 | $0.73 | $0.16 | $-0.44 | $-0.94 | $-0.03 | $0.00 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.04 | $0.12 | $0.70 | $0.15 | $-0.44 | $-0.94 | $-0.03 | $0.00 | |
| Shares Outstanding | 126.9 | 126.7 | 131.7 | 131.2 | 130.1 | 128.3 | 107.7 | 92.8 | 69.3 | 63.9 | 63.2 | |
| Diluted Shares Outstanding | 132.2 | 130.2 | 131.7 | 132.7 | 132.4 | 133.7 | 111.4 | 92.8 | 69.3 | 63.9 | 63.2 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.09 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.09 | ||
| Shares Outstanding | 126.9 | 126.9 | 126.9 | 126.3 | 131.7 | 132.6 | 132.6 | 131.9 | 130.9 | 131.3 | ||
| Diluted Shares Outstanding | 132.2 | 130.8 | 126.9 | 126.3 | 132.2 | 133.9 | 132.6 | 131.9 | 131.9 | 133.4 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 90.5 | 135.6 | 104.3 | 102.5 | 113.9 | 84.4 | 60.2 | 21.3 | 0.1 | 1.0 | 0.1 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 90.5 | 135.6 | 104.3 | 102.5 | 113.9 | 84.4 | 60.2 | 21.3 | 0.1 | 1.0 | 0.1 | |
| Accounts Receivable | 105.9 | 109.9 | 82.0 | 89.5 | 82.5 | 56.8 | 39.4 | 34.1 | 0.0 | 0.0 | 0.0 | |
| Inventory | 26.9 | 26.2 | 28.3 | 24.8 | 25.0 | 27.8 | 22.9 | 13.3 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 10.9 | 14.3 | 10.5 | 5.1 | 5.0 | 4.9 | 3.0 | 2.3 | 0.2 | 0.4 | 0.0 | |
| Total Current Assets | 234.2 | 285.9 | 225.0 | 222.6 | 227.0 | 174.3 | 125.6 | 71.1 | 0.3 | 1.4 | 0.1 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 64.4 | 73.1 | 110.0 | 135.6 | 94.3 | 89.9 | 88.6 | 104.3 | 98.2 | 88.9 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | |
| Total Cash & ST Investments | 64.4 | 73.1 | 110.0 | 135.6 | 94.3 | 89.9 | 88.6 | 104.3 | 98.2 | 88.9 | |
| Accounts Receivable | 168.8 | 120.4 | 103.3 | 109.9 | 101.3 | 105.9 | 96.1 | 82.0 | 89.3 | 93.6 | |
| Inventory | 39.6 | 33.0 | 29.3 | 26.2 | 27.0 | 26.9 | 27.7 | 28.3 | 27.9 | 25.4 | |
| Other Current Assets | 27.0 | 33.7 | 25.5 | 14.3 | 15.9 | 11.5 | 14.7 | 10.5 | 10.2 | 7.9 | |
| Total Current Assets | 299.7 | 260.2 | 268.2 | 285.9 | 238.5 | 234.2 | 227.2 | 225.0 | 225.6 | 216.4 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 126.5 | 126.2 | 156.3 | 145.7 | 128.3 | 60.1 | 47.2 | 39.6 | 0.0 | 0.0 | 0.0 | |
| Goodwill | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 25.5 | 25.5 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 14.1 | 12.5 | 15.9 | 20.8 | 25.7 | 30.6 | 20.8 | 26.1 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.5 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 5.9 | 5.0 | 6.0 | 1.5 | 1.5 | 0.7 | 0.9 | 0.6 | 312.5 | 310.0 | 0.3 | |
| Total Long-Term Assets | 209.0 | 211.9 | 235.0 | 226.8 | 216.3 | 120.2 | 95.1 | 92.5 | 312.5 | 310.0 | 0.3 | |
| Total Assets | 443.2 | 497.9 | 460.0 | 449.4 | 443.3 | 294.5 | 220.7 | 163.7 | 312.8 | 311.4 | 0.4 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 111.4 | 110.9 | 112.3 | 126.2 | 124.8 | 126.5 | 152.9 | 156.3 | 159.9 | 155.4 | |
| Goodwill | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | |
| Intangible Assets | 9.9 | 10.8 | 11.6 | 12.5 | 13.3 | 14.1 | 15.0 | 15.9 | 17.1 | 18.3 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15.9 | 0.0 | 0.0 | |
| Other Long-Term Assets | 14.4 | 8.7 | 5.8 | 5.0 | 5.0 | 5.9 | 6.7 | -9.9 | 1.3 | 1.4 | |
| Total Long-Term Assets | 210.1 | 200.9 | 199.2 | 211.9 | 207.8 | 209.0 | 231.3 | 235.0 | 237.1 | 233.9 | |
| Total Assets | 509.8 | 461.1 | 467.4 | 497.9 | 446.3 | 443.2 | 458.5 | 460.0 | 462.6 | 450.3 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 29.4 | 28.9 | 30.7 | 32.3 | 29.3 | 23.4 | 28.4 | 19.2 | 0.0 | 0.0 | 0.0 | |
| Short-Term Debt | 18.3 | 9.1 | 33.9 | 16.2 | 14.6 | 20.3 | 3.1 | 10.0 | 0.1 | 0.0 | 0.2 | |
| Other Current Liabilities | 34.1 | 35.2 | 13.1 | 26.4 | 2.3 | 2.1 | 5.8 | 6.8 | 3.8 | 0.5 | 0.2 | |
| Current Liabilities | 85.7 | 77.5 | 80.5 | 75.0 | 82.0 | 68.2 | 59.9 | 66.4 | 3.9 | 0.5 | 0.4 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 40.2 | 29.7 | 24.7 | 28.9 | 24.0 | 29.4 | 23.2 | 30.7 | 26.8 | 27.4 | |
| Short-Term Debt | 9.8 | 9.8 | 9.3 | 9.1 | 18.5 | 20.2 | 22.3 | 33.9 | 21.9 | 20.4 | |
| Other Current Liabilities | 40.3 | 23.5 | 31.0 | 35.2 | 34.7 | 32.3 | 36.8 | 13.1 | 26.6 | 24.0 | |
| Current Liabilities | 90.3 | 65.8 | 65.1 | 77.5 | 77.3 | 85.7 | 82.8 | 80.5 | 81.5 | 73.5 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 57.7 | 34.2 | 99.6 | 107.5 | 117.7 | 64.5 | 97.5 | 49.2 | 0.0 | 0.0 | 0.0 | |
| Capital Leases | 34.9 | 43.3 | 53.1 | 53.0 | 58.9 | 15.1 | 17.5 | 17.7 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 179.7 | 112.6 | 181.4 | 183.7 | 201.2 | 148.4 | 165.1 | 116.6 | 14.8 | 11.3 | 0.4 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 31.0 | 31.0 | 33.4 | 34.2 | 89.2 | 92.7 | 96.4 | 99.6 | 103.1 | 104.4 | |
| Capital Leases | 0.0 | 40.8 | 42.6 | 43.3 | 45.6 | 49.4 | 53.8 | 38.9 | 57.4 | 55.8 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 123.8 | 99.9 | 99.3 | 112.6 | 167.7 | 179.7 | 180.5 | 181.4 | 185.8 | 179.0 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 293.0 | 295.1 | 0.0 | |
| Retained Earnings | -60.1 | -40.1 | -41.0 | -45.3 | -60.1 | -153.1 | -171.0 | -130.2 | -2.3 | -0.2 | 0.0 | |
| Comprehensive Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Common Equity | 263.5 | 385.3 | 278.7 | 265.7 | 242.0 | 146.1 | 55.6 | 47.0 | 298.0 | 300.1 | 0.0 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -46.8 | -68.3 | -59.0 | -40.1 | -47.8 | -60.1 | -43.1 | -41.0 | -40.4 | -43.6 | |
| Comprehensive Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Common Equity | 386.0 | 361.2 | 368.1 | 385.3 | 278.5 | 263.5 | 278.0 | 278.7 | 276.9 | 271.3 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 111.0 | 43.3 | 119.4 | 123.8 | 132.3 | 84.8 | 100.6 | 59.3 | 0.1 | 0.0 | 0.2 | |
| Book Value | 263.5 | 385.3 | 278.7 | 265.7 | 242.0 | 146.1 | 55.6 | 47.0 | 298.0 | 300.1 | 0.0 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 386.0 | 361.2 | 368.1 | 385.3 | 278.5 | 263.5 | 278.0 | 278.7 | 276.9 | 271.3 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -16.5 | 37.0 | 0.9 | 4.9 | 15.5 | 94.9 | 17.9 | -40.5 | -64.8 | -2.1 | -0.2 | |
| Depreciation & Amortization | 22.6 | 18.6 | 17.0 | 23.4 | 18.0 | 16.7 | 7.5 | 9.4 | 7.0 | 0.0 | 0.0 | |
| Stock-Based Compensation | 9.8 | 13.3 | 10.6 | 9.0 | 6.6 | 3.9 | 1.7 | 0.9 | 1.1 | 0.0 | 303.8 | |
| Change Working Capital | -27.9 | -132.4 | -48.9 | -18.1 | -34.1 | -39.3 | -26.2 | -9.7 | -22.4 | 1.5 | -0.4 | |
| Change In Accounts Receivable | -15.5 | -115.8 | -31.8 | 5.5 | -8.8 | -30.2 | -18.8 | -4.7 | -7.1 | 0.0 | 0.0 | |
| Change In Accounts Payable | 1.3 | -0.5 | -2.4 | -0.1 | 3.3 | 3.8 | -0.6 | 4.7 | -0.1 | 0.0 | 0.0 | |
| Change In Inventories | -6.1 | -17.9 | -6.2 | 6.6 | -9.4 | -9.3 | -6.7 | -11.1 | -5.0 | 0.0 | 0.0 | |
| Other Non-cash Items | 94.6 | 43.6 | 45.4 | 9.6 | 16.8 | 17.8 | 5.8 | 6.1 | 18.3 | 0.0 | -303.8 | |
| Cash from Operations | 21.9 | 0.0 | 0.0 | 30.9 | 24.9 | 62.0 | 6.8 | -33.5 | -60.7 | -0.6 | -0.6 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 43.7 | 21.6 | -9.4 | -18.8 | 7.7 | 12.3 | -17.0 | -2.1 | -0.6 | 3.2 | |
| Depreciation & Amortization | 6.9 | 7.0 | 4.6 | 6.3 | 6.4 | 4.4 | 4.2 | 6.2 | 6.3 | 3.8 | |
| Stock-Based Compensation | 4.3 | 0.0 | 2.5 | 3.4 | 0.0 | 2.7 | 2.6 | 2.4 | 2.4 | 2.4 | |
| Change Working Capital | -43.7 | -29.9 | -38.1 | -20.7 | -6.8 | -13.8 | -7.6 | -20.7 | -2.7 | 3.0 | |
| Change In Accounts Receivable | -51.5 | -50.7 | -19.3 | 5.7 | -8.8 | 3.0 | -10.9 | -15.1 | 7.3 | 3.2 | |
| Change In Accounts Payable | -1.2 | -1.0 | 4.1 | -2.5 | 3.7 | -3.9 | 2.2 | -4.4 | 3.6 | -0.1 | |
| Change In Inventories | -3.0 | 0.9 | -7.2 | -8.7 | -0.5 | 7.9 | 2.7 | -4.7 | -0.7 | -3.4 | |
| Other Non-cash Items | 12.6 | 8.2 | 8.5 | 11.2 | 6.5 | 5.3 | 22.6 | 4.1 | 3.1 | 1.1 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.6 | 16.7 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -13.4 | -14.2 | -10.0 | -24.4 | -33.9 | -31.2 | -21.1 | -6.2 | -1.9 | 0.0 | 0.0 | |
| Acquisitions | -0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -5.8 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.1 | 0.0 | 0.0 | 0.0 | -310.0 | |
| Cash from Investing | -13.4 | 0.0 | 0.0 | -24.4 | -33.9 | -31.2 | -24.8 | -6.2 | -1.9 | 0.0 | -310.0 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -4.7 | -2.2 | -3.6 | -3.6 | -3.4 | -2.6 | -1.9 | -2.2 | -3.3 | -6.0 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.7 | 0.8 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.7 | -0.8 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.3 | -6.0 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -6.6 | 0.0 | 0.0 | -5.2 | -3.0 | -65.2 | -25.9 | -18.9 | -22.7 | 0.0 | -0.3 | |
| Debt Issued | -7.2 | 43.3 | -76.0 | 0.7 | -5.5 | 112.7 | 10.1 | 60.2 | 81.9 | 0.1 | 0.1 | |
| Issuance of Common Stock | -0.6 | 0.0 | 0.0 | 0.0 | 2.1 | 0.0 | 64.7 | 50.3 | 92.0 | 0.0 | 303.8 | |
| Repurchase of Common Stock | 0.3 | 0.0 | -25.5 | 0.0 | 0.0 | 0.0 | 0.0 | -6.8 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -57.9 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -1.2 | 0.0 | 0.0 | -0.3 | -1.3 | 64.2 | 3.7 | 111.9 | 12.3 | -0.3 | 8.0 | |
| Cash from Financing | -7.6 | 0.0 | 0.0 | -5.5 | -2.2 | -1.0 | 42.5 | 78.7 | 81.6 | -0.3 | 311.5 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.8 | -1.4 | |
| Debt Issued | 40.8 | 0.0 | -1.8 | -0.7 | -64.4 | -5.2 | -5.8 | -0.7 | -3.9 | 1.7 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.8 | 0.0 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | -25.5 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.8 | -1.4 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 1.0 | -41.8 | 31.8 | 1.0 | -11.2 | 29.7 | 24.4 | 39.0 | 19.0 | -0.9 | 0.9 | |
| Closing Cash Balance | 90.5 | 94.3 | 136.2 | 104.3 | 103.3 | 114.5 | 84.8 | 60.4 | 21.4 | 0.1 | 1.0 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 30.0 | -9.4 | -36.8 | -25.6 | 41.2 | 4.4 | 1.1 | -15.0 | 5.5 | 9.3 | |
| Closing Cash Balance | 94.3 | 64.4 | 73.7 | 110.5 | 136.2 | 94.9 | 90.5 | 89.3 | 104.3 | 98.8 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 8.5 | -24.5 | 4.2 | 6.6 | -9.0 | 30.8 | -14.3 | -39.8 | -62.6 | -0.6 | -0.6 | |
| Real Free Cash Flow | -1.2 | -37.8 | -6.4 | -2.4 | -15.6 | 26.9 | -16.0 | -40.7 | -63.7 | -0.6 | -304.4 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 34.8 | 0.8 | -36.5 | -23.6 | 7.6 | 6.1 | 2.9 | -12.4 | 7.3 | 10.8 | |
| Real Free Cash Flow | 30.4 | 0.8 | -39.1 | -26.9 | 7.6 | 3.4 | 0.3 | -14.8 | 4.9 | 8.3 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 486.9 | 24.7 | 2356.8 |
| P/S | 1.1 | 8.5 | 70.5 |
| P/B | 1.3 | 9.1 | 2015.4 |
| P/FCF | -8.5 | -107.5 | 7573.5 |
| Market cap | $0.8 | $3.2 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 8 % | 23.1 % | 0 % |
| Debt to Income | 110.2 % | -7.3 % | 0 % |
| Debt to Free cash flow | -117.6 % | -52.1 % | 0 % |
| Interest expense percentage | 1.4 % | 2.6 % | 26.2 % |
| Current ratio | 3.3 | 2.3 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 9.6 % | -12.3 % | 0 % |
| ROA | 7.3 % | 0.5 % | 0 % |
| CapEx to Revenue | 2.8 % | 3.3 % | 6 % |
| RaD to Revenue | 0 % | 5.4 % | 0 % |
| ROEM | 648,956.3 | 264451.5 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 74.5 % | -133.5 % | 74.8 % |
| Operating margin | -1.8 % | -146.5 % | 35 % |
| Net margin | 0.2 % | -71.9 % | 34.1 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0.1 % | 0 % |
| Dividend payout percentage | 0 % | -1.9 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 130.8 mil | 94.7 mil |
| Employee count | 0.9 tis | 0.7 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
